<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208698</url>
  </required_header>
  <id_info>
    <org_study_id>CIN-102-122</org_study_id>
    <nct_id>NCT04208698</nct_id>
  </id_info>
  <brief_title>A Scintigraphy Study in Adults With Diabetic Gastroparesis</brief_title>
  <official_title>A Randomized, Double-Blind Placebo-Controlled Scintigraphy Study to Investigate the Effect of CIN-102 on Gastric Emptying and Antral Contractility in Adults With Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CinDome Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CinDome Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the&#xD;
      effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic&#xD;
      gastroparesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the&#xD;
      effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic&#xD;
      gastroparesis. The population for this study is adult patients 18 to 70 years old with Type 1&#xD;
      or Type 2 diabetes and a diagnosis of diabetic gastroparesis. The study will consist of two&#xD;
      cohorts with approximately 15 subjects in each cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial was terminated due to the impact of COVID-19 on trial activities.&#xD;
  </why_stopped>
  <start_date type="Actual">February 17, 2020</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate the Change From Baseline in Gastric Percentage Retention of a Radiolabeled Meal After Dosing CIN-102 in Patients With Diabetic Gastroparesis.</measure>
    <time_frame>Baseline to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Incidence of Treatment-emergent Adverse Effects as Measured by Safety Laboratory Data and Patient Reported Events.</measure>
    <time_frame>Screening to Day 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Effect of CIN-102 on Antral Contractility as Measured by Dynamic Antral Scintigraphy (DAS), a Non-invasive Technique for the Assessment of Post-prandial Gastric Contractions Will be Used to Evaluate Antral Motility.</measure>
    <time_frame>Baseline to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Effect of CIN-102 on Gastric Accommodation to be Evaluated Using Data Captured During the Total-stomach Gastric Emptying Study to Measure Food Retention in the Stomach During the First Two Post-prandial Hours.</measure>
    <time_frame>Baseline to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Asses the Change From Baseline in ANMS GCSI-DD Total Scores</measure>
    <time_frame>Day -14 to 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Change From Baseline in ANMS GCSI-DD Subscale Scores</measure>
    <time_frame>Day -14 to 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Change From Baseline in Symptom Severity as Measured by the PAGI-SYM</measure>
    <time_frame>Baseline to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess the Change in Baseline of the Clinical Grading Assessment Scale</measure>
    <time_frame>Baseline to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Diabetic Gastroparesis</condition>
  <arm_group>
    <arm_group_label>CIN-102 Tablets Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CIN-102 tablets by mouth twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for CIN-102 Dose 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets by mouth twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIN-102 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CIN-102 tablets by mouth twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for CIN-102 Dose 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets by mouth twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIN-102 Dose 1</intervention_name>
    <description>Deuterated domperidone (deudomperidone)</description>
    <arm_group_label>CIN-102 Tablets Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CIN-102 Dose 2</intervention_name>
    <description>Deuterated domperidone (deudomperidone)</description>
    <arm_group_label>CIN-102 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for CIN-102</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo for CIN-102 Dose 1</arm_group_label>
    <arm_group_label>Placebo for CIN-102 Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients 18 to 70 years old, inclusive.&#xD;
&#xD;
          -  Type 1 or Type 2 diabetes mellitus, according to American Diabetes Association&#xD;
             criteria&#xD;
&#xD;
          -  Current diagnosis of diabetic gastroparesis.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18 and 40 kg/m2, inclusive.&#xD;
&#xD;
          -  Glycosylated hemoglobin level &lt;11% at Screening.&#xD;
&#xD;
          -  Willing to abstain from tobacco or nicotine-containing product use after midnight on&#xD;
             the day of the DAS test and throughout the time that gastric emptying is being imaged.&#xD;
&#xD;
          -  Willing to abstain from grapefruit, grapefruit products, star fruit, star fruit&#xD;
             products, and Seville oranges from 72 hours prior to the Randomization Visit until end&#xD;
             of study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of, or current, clinically significant arrhythmias as judged by the&#xD;
             Investigator, including ventricular tachycardia, ventricular fibrillation, atrial&#xD;
             fibrillation, and Torsades de Pointes. Patients with minor forms of ectopy (eg,&#xD;
             premature atrial contractions) are not necessarily excluded.&#xD;
&#xD;
          -  Clinically significant bradycardia with a resting heart rate under 50 beats per&#xD;
             minute, sinus node dysfunction, or heart block.&#xD;
&#xD;
          -  Prolonged heart rate-corrected QT interval using Fridericia's formula (QTcF) (QTcF&#xD;
             &gt;450 msec for males or QTcF &gt;470 msec for females) based on the average of triplicate&#xD;
             ECGs.&#xD;
&#xD;
          -  A personal or family history of long QT syndrome, Torsades de pointes, or other&#xD;
             complex ventricular arrhythmias or family history of sudden death.&#xD;
&#xD;
          -  Evidence (based on Screening or Baseline assessments) or history of clinically&#xD;
             significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal,&#xD;
             cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug&#xD;
             allergies); surgical conditions; cancer (with the exception of basal or squamous cell&#xD;
             carcinoma of the skin and cancer that resolved or has been in remission for &gt;5 years&#xD;
             prior to the Screening Visit); or any condition that, in the Investigator's opinion,&#xD;
             might significantly interfere with the absorption, distribution, metabolism, or&#xD;
             excretion of the study drug.&#xD;
&#xD;
          -  History of prolactin-releasing pituitary tumor (ie, prolactinoma).&#xD;
&#xD;
          -  Allergic to egg or intolerant to gluten.&#xD;
&#xD;
          -  History of alcoholism or drug abuse within 2 years prior to dosing as defined by the&#xD;
             Diagnostic and Statistical Manual of Mental Disorders, 4th Edition.&#xD;
&#xD;
          -  Known or suspected gastric outlet obstruction (eg, peptic stricture) or other&#xD;
             gastrointestinal mechanical obstruction.&#xD;
&#xD;
          -  Known history or current diagnosis of intestinal malabsorption or pancreatic exocrine&#xD;
             disease.&#xD;
&#xD;
          -  History or presence of any medical condition or psychiatric disease, which, in the&#xD;
             opinion of the Investigator, could interfere with the conduct of the study or would&#xD;
             put the patient at unacceptable risk.&#xD;
&#xD;
          -  Judged by the Investigator, after reviewing medical and psychiatric history, physical&#xD;
             examination, and laboratory evaluation, to be unsuitable for any other reason that may&#xD;
             either place the patient at increased risk during participation or interfere with the&#xD;
             interpretation of the study outcomes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Murphy, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>CinRx Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <results_first_submitted>July 16, 2021</results_first_submitted>
  <results_first_submitted_qc>August 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2021</results_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT04208698/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two patients entered the Screening Period. No patients were randomized to the Study Treatment Period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Screening Period</title>
          <description>Screening Period</description>
        </group>
        <group group_id="P2">
          <title>CIN-102 Tablets Dose 1</title>
          <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 1: Deuterated domperidone (deudomperidone)</description>
        </group>
        <group group_id="P3">
          <title>Placebo for CIN-102 Dose 1</title>
          <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
        </group>
        <group group_id="P4">
          <title>CIN-102 Dose 2</title>
          <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 2: Deuterated domperidone (deudomperidone)</description>
        </group>
        <group group_id="P5">
          <title>Placebo for CIN-102 Dose 2</title>
          <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two patients entered the Screening Period. No patients were randomized to the Treatment Period.</population>
      <group_list>
        <group group_id="B1">
          <title>Screening Period</title>
          <description>Screening Period</description>
        </group>
        <group group_id="B2">
          <title>CIN-102 Tablets Dose 1</title>
          <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 1: Deuterated domperidone (deudomperidone)</description>
        </group>
        <group group_id="B3">
          <title>Placebo for CIN-102 Dose 1</title>
          <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
        </group>
        <group group_id="B4">
          <title>CIN-102 Dose 2</title>
          <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 2: Deuterated domperidone (deudomperidone)</description>
        </group>
        <group group_id="B5">
          <title>Placebo for CIN-102 Dose 2</title>
          <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Evaluate the Change From Baseline in Gastric Percentage Retention of a Radiolabeled Meal After Dosing CIN-102 in Patients With Diabetic Gastroparesis.</title>
        <time_frame>Baseline to Day 14</time_frame>
        <population>No patients were randomized to the study treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CIN-102 Tablets Dose 1</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 1: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo for CIN-102 Dose 1</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
          <group group_id="O3">
            <title>CIN-102 Dose 2</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 2: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O4">
            <title>Placebo for CIN-102 Dose 2</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Change From Baseline in Gastric Percentage Retention of a Radiolabeled Meal After Dosing CIN-102 in Patients With Diabetic Gastroparesis.</title>
          <population>No patients were randomized to the study treatment period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Incidence of Treatment-emergent Adverse Effects as Measured by Safety Laboratory Data and Patient Reported Events.</title>
        <time_frame>Screening to Day 20</time_frame>
        <population>No patients were randomized to the study treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CIN-102 Tablets Dose 1</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 1: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo for CIN-102 Dose 1</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
          <group group_id="O3">
            <title>CIN-102 Dose 2</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 2: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O4">
            <title>Placebo for CIN-102 Dose 2</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Incidence of Treatment-emergent Adverse Effects as Measured by Safety Laboratory Data and Patient Reported Events.</title>
          <population>No patients were randomized to the study treatment period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Effect of CIN-102 on Antral Contractility as Measured by Dynamic Antral Scintigraphy (DAS), a Non-invasive Technique for the Assessment of Post-prandial Gastric Contractions Will be Used to Evaluate Antral Motility.</title>
        <time_frame>Baseline to Day 14</time_frame>
        <population>No patients were randomized to the study treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CIN-102 Tablets Dose 1</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 1: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo for CIN-102 Dose 1</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
          <group group_id="O3">
            <title>CIN-102 Dose 2</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 2: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O4">
            <title>Placebo for CIN-102 Dose 2</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Effect of CIN-102 on Antral Contractility as Measured by Dynamic Antral Scintigraphy (DAS), a Non-invasive Technique for the Assessment of Post-prandial Gastric Contractions Will be Used to Evaluate Antral Motility.</title>
          <population>No patients were randomized to the study treatment period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Effect of CIN-102 on Gastric Accommodation to be Evaluated Using Data Captured During the Total-stomach Gastric Emptying Study to Measure Food Retention in the Stomach During the First Two Post-prandial Hours.</title>
        <time_frame>Baseline to Day 14</time_frame>
        <population>No patients were randomized to the study treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CIN-102 Tablets Dose 1</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 1: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo for CIN-102 Dose 1</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
          <group group_id="O3">
            <title>CIN-102 Dose 2</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 2: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O4">
            <title>Placebo for CIN-102 Dose 2</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Effect of CIN-102 on Gastric Accommodation to be Evaluated Using Data Captured During the Total-stomach Gastric Emptying Study to Measure Food Retention in the Stomach During the First Two Post-prandial Hours.</title>
          <population>No patients were randomized to the study treatment period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Asses the Change From Baseline in ANMS GCSI-DD Total Scores</title>
        <time_frame>Day -14 to 14</time_frame>
        <population>No patients were randomized to the study treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CIN-102 Tablets Dose 1</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 1: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo for CIN-102 Dose 1</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
          <group group_id="O3">
            <title>CIN-102 Dose 2</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 2: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O4">
            <title>Placebo for CIN-102 Dose 2</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>To Asses the Change From Baseline in ANMS GCSI-DD Total Scores</title>
          <population>No patients were randomized to the study treatment period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Change From Baseline in ANMS GCSI-DD Subscale Scores</title>
        <time_frame>Day -14 to 14</time_frame>
        <population>No patients were randomized to the study treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CIN-102 Tablets Dose 1</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 1: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo for CIN-102 Dose 1</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
          <group group_id="O3">
            <title>CIN-102 Dose 2</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 2: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O4">
            <title>Placebo for CIN-102 Dose 2</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Change From Baseline in ANMS GCSI-DD Subscale Scores</title>
          <population>No patients were randomized to the study treatment period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Change From Baseline in Symptom Severity as Measured by the PAGI-SYM</title>
        <time_frame>Baseline to Day 14</time_frame>
        <population>No patients were randomized to the study treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CIN-102 Tablets Dose 1</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 1: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo for CIN-102 Dose 1</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
          <group group_id="O3">
            <title>CIN-102 Dose 2</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 2: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O4">
            <title>Placebo for CIN-102 Dose 2</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Change From Baseline in Symptom Severity as Measured by the PAGI-SYM</title>
          <population>No patients were randomized to the study treatment period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Change in Baseline of the Clinical Grading Assessment Scale</title>
        <time_frame>Baseline to Day 14</time_frame>
        <population>No patients were randomized to the study treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>CIN-102 Tablets Dose 1</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 1: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo for CIN-102 Dose 1</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
          <group group_id="O3">
            <title>CIN-102 Dose 2</title>
            <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 2: Deuterated domperidone (deudomperidone)</description>
          </group>
          <group group_id="O4">
            <title>Placebo for CIN-102 Dose 2</title>
            <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Change in Baseline of the Clinical Grading Assessment Scale</title>
          <population>No patients were randomized to the study treatment period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately one month.</time_frame>
      <desc>No patients were randomized to the study treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>CIN-102 Tablets Dose 1</title>
          <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 1: Deuterated domperidone (deudomperidone)</description>
        </group>
        <group group_id="E2">
          <title>Placebo for CIN-102 Dose 1</title>
          <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
        </group>
        <group group_id="E3">
          <title>CIN-102 Dose 2</title>
          <description>CIN-102 tablets by mouth twice daily for 14 days&#xD;
CIN-102 Dose 2: Deuterated domperidone (deudomperidone)</description>
        </group>
        <group group_id="E4">
          <title>Placebo for CIN-102 Dose 2</title>
          <description>Placebo tablets by mouth twice daily for 14 days&#xD;
Placebo for CIN-102: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>CinDome Pharma, Inc.</organization>
      <phone>844-531-1834</phone>
      <email>info@cinrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

